Anzurstobart (CC-95251, BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPalpha antibody that blocks the binding of CD47 to SIRPalpha. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research.
